Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells

Table 1 Outcomes of immunotherapy in the study group

Patient no.	Sex	Age (yr)	Pre-treatment KPS	No. of injection	DTH positive≥5 mm	Adverse events	Tumor markers AFP	Imaging response	Survival months till now
1	F	38	70	4	60 mm	Fever, rash	Decrease	PD	14.4D
2	M	46	100	5	70 mm	Fever, rash, erythema	Decrease	PD	19.6A
3	M	55	75	6	45 mm	Fever, multiple erythema	Decrease	PR	18.8A
4	M	65	90	2	60 mm	Fever	Decrease	NC	16.8D
5	M	72	70	5	25 mm	Fever, rash	Decrease	NC	15.2D
6	M	78	90	6	65 mm	Fatigue, fever	Decrease	PR	16.0D
7	M	40	80	4	60 mm	Fever, rash	Decrease	NC	15.6D
8	M	54	70	6	5 mm	Fever	Increase	PD	17.6D
9	F	63	95	7	50 mm	Rash	Decrease	PR	20.0A

AFP: α-fetoprotein; PR: Partial response; PD: Progress disease, NC: No change; A: Still alive; D: Dead; KPS: Karnofsky performance status; DTH: Delayed-type hypersensitivity.

Table 2 Ratios of post- and pre-immunotherapy in cell populations and interferon-γ expression levels

Patient no.	CD8+post vs pre	CD45RO+post vs pre	CD56+post vs pre	IFN-γfold increasepost vs pre
1	5.09	6.78	4.81	15.32
2	5.22	4.97	5.66	12.25
3	6.33	3.78	4.77	12.45
4	4.81	1.42	1.39	11.11
5	2.15	2.43	2.17	3.88
6	3.67	3.66	5.86	7.94
7	3.78	3.94	2.81	8.31
8	0.55	2.02	0.65	1.03
9	5.23	6.67	3.55	12.73

IFN: Interferon; CD: Cluster of differentiation..